10 results about "Indapamide" patented technology

The invention relates to the technical field of medicines, and particularly discloses a compound antihypertensive pharmaceutical composition. The pharmaceutical composition provided by the invention selects sacubitril valsartan sodium and indapamide as active ingredients, and within a prescription dosage range limited by the application, the two medicines can fully realize an antihypertensive effect through a synergistic effect, and the renal function of a patient is effectively improved. Through cooperation of the two components, the hypertension symptom of a patient can be effectively controlled, the adverse reaction is not obvious, and the compliance of the patient can be improved by adopting the compound preparation, so that the control on the blood pressure of the patient is enhanced.

The invention provides a pharmaceutical composition. The pharmaceutical composition is prepared from enalapril, indapamide, metoprolol, amlodipine, folic acid and pharmaceutically acceptable auxiliary materials. The composition provided by the invention has the advantages that the composition has remarkable beneficial effects of reducing blood pressure and improving cardiac hemodynamics, and is particularly suitable for patients with hypertension secondary left ventricular hypertrophy and chronic heart failure. Meanwhile, the compound form of the product can improve the taking compliance of patients.

The invention relates to a hypertension implant rod and a preparation method thereof, and relates to the technical field of hypertension implant rods, the hypertension implant rod comprises a quick release layer, a slow release layer and a long-acting regulation and control layer from outside to inside, the quick release layer comprises, by mass, 60-70% of bacterial cellulose (BC), 15-25% of polydopamine (PDA), 3-8% of ciprofloxacin, 3-8% of protamine and 4-6% of indapamide, the slow release layer comprises, by mass, 20-30% of a long-acting regulation and control layer, and the long-acting regulation and control layer comprises, by mass, 20-30% of a slow release layer and 20-30% of a long-acting regulation and control layer. The sustained release layer is prepared from 55 to 65 percent of polylactic acid-glycolic acid copolymer, 20 to 30 percent of cross-linked gelatin, 8 to 12 percent of lacidipine and 4 to 6 percent of spirolactone, and the long-acting regulation and control layer is prepared from 65 to 75 percent of L-polylactic acid, 20 to 30 percent of beta-glycine crystal, 3 to 5 percent of silk fibroin (SF), 0.5 to 1.0 percent of calcitonin gene related peptide CGRP and 0.1 to 0.3 percent of neuropeptide Y. The hypertension implant rod can be matched with various treatment cycles through gradient degradation, realizes'on-demand treatment ', is high in biocompatibility, is suitable for subcutaneous implantation, and is convenient and safe to operate.

The invention relates to an indapamide sustained-release pharmaceutical composition which contains indapamide, fucoidin, a polyvinyl acetate povidone mixture kollidon SR, a disintegrating agent and a lubricant, and discloses a preparation method of the indapamide sustained-release pharmaceutical composition, and the indapamide sustained-release pharmaceutical composition provided by the invention has the advantages of drug dissolution meeting requirements, no burst release, simple process, and reduction of electrolyte flocculation and diabetes incidence.

The present invention relates to a pharmaceutical composite formulation containing candesartan, amlodipine, and indapamide as active ingredients for preventing or treating hypertension. By including candesartan, amlodipine, and indapamide at low doses, the pharmaceutical composite formulation according to the present invention can reduce side effects that may occur due to excessive blood pressure reduction, and can be utilized as a composite formulation for preventing or treating hypertension owing to sufficient tolerability and excellent blood pressure-lowering effects.

The invention provides a pharmaceutical composition of ARNi and indapamide and application of the pharmaceutical composition. The pharmaceutical composition can be used for diseases such as hypertension and / or heart failure.

The invention provides a sacubitril-valsartan sodium indapamide sustained-release tablet and a preparation method thereof, the sacubitril-valsartan sodium indapamide sustained-release tablet is of a double-layer tablet structure and comprises a first indapamide sustained-release layer and a second sacubitril-valsartan sodium quick-release layer, and the sacubitril-valsartan sodium indapamide sustained-release tablet can be prepared by adjusting the type and dosage of sustained-release materials in the indapamide sustained-release layer. According to the type and dosage of the disintegrating agent and the dosage of the adhesive in the sacubitril valsartan sodium quick release layer, the process of the double-layer tablet is stable, the release behavior of the double-layer tablet is similar to that of a single preparation, and the consistency of the curative effect of the medicine is ensured.

A process for the synthesis of 1-amino-2-methyl-2,3-dihydroindole 3 or an acid addition salt thereof comprising the steps: (a) providing 2-methyl-2,3-dihydro-1H-indole 1 (b) nitrosating the 2-methyl-2,3-dihydro-1H-indole 1 with a nitrosation agent to afford 1-nitroso-2-methyl-2,3-dihydroindole 2 (c) reducing the 1-nitroso-2-methyl-2,3-dihydroindole 2 with thiourea dioxide as reducing agent to afford the 1-amino-2-methyl-2,3-dihydroindole 3 and (d) optionally, converting the 1-amino-2-methyl-2,3-dihydroindole 3 into the acid addition salt thereof. 1-amino-2-methyl-2,3-dihydroindole is a key intermediate in the industrial synthesis of indapamide.

The application provides a sacubitril valsartan sodium indapamide sustained-release tablet and a preparation method thereof. The tablet is a double-layer tablet structure, comprising a first layer of an indapamide sustained-release layer and a second layer of a sacubitril valsartan sodium immediate-release layer. By adjusting the type and amount of the sustained-release material in the indapamide sustained-release layer, the type and amount of the disintegrant in the sacubitril valsartan sodium immediate-release layer and the amount of the binder, the double-layer tablet process is stable, the release behavior is similar to that of single preparation, and the consistency of the drug efficacy is ensured.

To provide a new effective and acceptable pharmaceutical composition for reducing hypertension.SOLUTION: (a) telmisartan, (b) indapamide, and (c) amlodipine besylate, wherein the dose of telmisartan is from about 8mg to about 12mg or from about 12mg to about 16mg, the dose of indapamide is from about 0. 5mg to about 0. 75mg or from about 0. 75mg to about 1. 0mg, and the dose of amlodipine besylate is from about 1mg to about 1. or from about 1. to about, and wherein the pharmaceutical composition further comprises one or more cholesterol lowering active agents. 5mg 5mg 2mg.SELECTED DRAWING: None